BMC Cancer: Evaluating the efficacy of a weekly low-dose bevacizumab combination regimen in patients with platinum-resistant ovarian cancer

Bevacizumab is commonly used in the treatment of ovarian cancer patients
.

Recently, a Japanese team published the results of a study in the journal BMC Cancer to evaluate the efficacy of weekly low-dose bevacizumab versus monthly high-dose bevacizumab in patients with platinum-resistant ovarian cancer

Bevacizumab is commonly used in the treatment of ovarian cancer patients

The study retrospectively included patients treated with bevacizumab in two hospitals.
Patients in group A were treated with weekly low-dose bevacizumab (100 mg on d1 and 8, 200 mg on d15), and patients in group B were treated with monthly high-dose bevacizumab.
Dose bevacizumab (15 mg/kg, d1) treatment
.

The curative effects of the two groups were compared

The study retrospectively included patients treated with bevacizumab in two hospitals.

The study included 44 cases in group A and 33 cases in group
B.

The best response, response rate and clinical benefit rate were not statistically different between the two groups, but the duration of remission in group A was significantly longer than that in group B, 8 (0–37) months and 5 (0–10) months, respectively month, there was a statistical difference (p < 0.

The study included 44 cases in group A and 33 cases in group

The median PFS of patients in group A was better than that in group B (p<0.

In multivariate analysis of PFS, weekly low-dose bevacizumab treatment was an independent good prognostic factor for PFS (HR=0.
53, 95%CI 0.
29–0.
95, p=0.
03)
.

In multivariate analysis of PFS, weekly low-dose bevacizumab treatment was an independent good prognostic factor for PFS (HR=0.
53, 95%CI 0.
29–0.
95, p=0.
03)
.

In multivariate analysis of PFS, weekly low-dose bevacizumab treatment was an independent good prognostic factor for PFS (HR=0.

Group A patients developed grade 3/4 anemia (p<0.
01), grade 3/4 neutropenia (p<0.
01), grade 3/4 hypertension (p<0.
01), intestinal obstruction (p<0.
01) and Thromboembolic events (p<0.
01) were significantly lower than those in group
B.

In group A, patients treated with gemcitabine + oxaliplatin, pegylated liposomal doxorubicin, and other regimens had better PFS (6, 12, and 5 months, respectively, p < 0.

Group A patients developed grade 3/4 anemia (p<0.

In conclusion, the study shows that weekly low-dose bevacizumab combination therapy improves the prognosis of patients with platinum-resistant ovarian cancer compared with monthly high-dose bevacizumab, which needs further verification in the future
.

In conclusion, the study shows that weekly low-dose bevacizumab combination therapy improves the prognosis of patients with platinum-resistant ovarian cancer compared with monthly high-dose bevacizumab, which needs further verification in the future
.

Studies have shown that weekly low-dose bevacizumab combination therapy improves the prognosis of patients with platinum-resistant ovarian cancer compared with monthly high-dose bevacizumab, and further validation is needed in the future
.
Studies have shown that weekly low-dose bevacizumab combination therapy improves the prognosis of patients with platinum-resistant ovarian cancer compared with monthly high-dose bevacizumab, and further validation is needed in the future
.

Original source:

Original source:

Suminokura J, Miyamoto M, Yoshikawa T, Kouta H, Kikuchi Y, Hada T, Ishibashi H, Ito T, Iwahashi H, Kakimoto S, Suzuki R, Matsuura H, Kishimoto N, Takano M.
Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
BMC Cancer.
2022 Feb 16;22(1):176.
doi: 10.
1186/s12885-022-09271-3.
PMID: 35172766.

Suminokura J, Miyamoto M, Yoshikawa T, Kouta H, Kikuchi Y, Hada T, Ishibashi H, Ito T, Iwahashi H, Kakimoto S, Suzuki R, Matsuura H, Kishimoto N, Takano M.
Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
BMC Cancer.
2022 Feb 16;22(1):176.
doi: 10.
1186/s12885-022-09271-3.
PMID: 35172766.
Leave a comment